跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 538,122 条关于
“Severe Myoclonic Epilepsy of Infancy”
全部
538,122
临床试验
489,450
药物
4,575
机构
3,310
资讯
40,787
去年
Global Clinical Trials for Dravet Syndrome Reviewed in 2024
去年
FDA Approves First 3D-Printed Epilepsy Drug for Feeding Tube Administration
去年
Real-World Safety Analysis Reveals New Adverse Events for Fenfluramine in Rare Epilepsy Syndromes
去年
NHS Approves Fenfluramine for Children with Lennox-Gastaut Syndrome, Offering New Hope for Severe Epilepsy Treatment
去年
Actio Biosciences Receives FDA Clearance and Fast Track Designation for First-in-Class KCNT1 Epilepsy Treatment
4个月前
Actio Biosciences Initiates Phase 1b/2 Trial of ABS-1230 for Rare Pediatric Epilepsy
去年
New Toolkit Shows Promise in Improving Sickle Cell Trait Documentation During Infancy
上个月
Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million, Securing First-in-Class KCNT1 Epilepsy Therapy ABS-1230
去年
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Dravet Syndrome Pipeline
28天前
Eight-month-old becomes first in world to receive precision medicine for KCNT1-related catastrophic epilepsy
第 1 页，共 4079 页
上一页
下一页
